
Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) – Equities research analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Voyager Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($1.41) per share for the year, down from their prior forecast of ($1.32). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at $0.12 EPS.
A number of other brokerages have also commented on VYGR. Weiss Ratings lowered Voyager Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Wall Street Zen downgraded Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.
Voyager Therapeutics Price Performance
Shares of Voyager Therapeutics stock opened at $1.63 on Tuesday. The stock has a 50-day moving average price of $2.34 and a 200 day moving average price of $3.34. Voyager Therapeutics has a 1 year low of $1.58 and a 1 year high of $5.48.
Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. Voyager Therapeutics had a negative return on equity of 63.42% and a negative net margin of 416.32%. The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $6.35 million.
Institutional Investors Weigh In On Voyager Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Voyager Therapeutics in the second quarter worth about $18,102,000. Renaissance Technologies LLC increased its holdings in shares of Voyager Therapeutics by 95.0% during the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock valued at $2,231,000 after acquiring an additional 281,574 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Voyager Therapeutics by 69.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 573,237 shares of the company’s stock valued at $1,536,000 after acquiring an additional 234,760 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Voyager Therapeutics in the 2nd quarter valued at approximately $513,000. Finally, Seven Fleet Capital Management LP lifted its holdings in Voyager Therapeutics by 100.0% in the 2nd quarter. Seven Fleet Capital Management LP now owns 230,406 shares of the company’s stock worth $772,000 after purchasing an additional 115,203 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.
Featured Articles
- Five stocks we like better than Voyager Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
